Brainlab AG Contemplates IPO in Frankfurt, Potential Valuation of €2 Billion

Investing.com -- Medical technology company Brainlab AG is reportedly evaluating options for an initial public offering (IPO) in Frankfurt, according to sources familiar with the matter cited by Bloomberg. The Munich-based firm, known for its advancements in medical technology, has sought banking offers for a potential stock sale, according to the sources.

The IPO could take place in the second half of 2025, potentially valuing the company at around €2 billion ($2.1 billion). However, these plans are still in discussion, and the potential size and timing of the IPO could change.

In response to inquiries from Bloomberg News, Brainlab stated, "Brainlab keeps all options open to promote long-term growth and maximize shareholder value." The company noted that no decision regarding an IPO has been made yet and that no authority has been granted to banks.

Brainlab, which is working with an advisor to obtain banking offers for a stock sale, did not provide further details regarding the potential IPO. Sources who wished to remain anonymous due to the sensitive nature of the information emphasized that the company's evaluations are ongoing.